Cubist Pharmaceuticals (CBST -1.3%) slips on a less-than-stellar initiation at Credit Suisse...
Cubist Pharmaceuticals (CBST -1.3%) slips on a less-than-stellar initiation at Credit Suisse with a Neutral rating and a $52 price target. The firm says it expects that positive CXA-201 data in the second half will strengthen confidence in the long-term sustainability of it's antibiotic franchise and be the impetus for global expansion.
From other sites
at Financial Times (Sun, 12:23PM)
at Nasdaq.com (Apr 27, 2015)
at Investopedia (Apr 10, 2015)
at Zacks.com (Apr 9, 2015)
at Zacks.com (Mar 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs